PharmaVoice
OCTOBER 21, 2024
Providers struggle with time-consuming processes. Patients are waiting for therapy. Embedded EMR system solutions can streamline therapy initiation and improve outcomes.
Fierce Pharma
OCTOBER 22, 2024
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job in a new presentation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
OCTOBER 22, 2024
Avandra Imaging, a federated network for de-identified imaging data, emerged from stealth at HLTH — as well as announced a partnership with Datavant. The post Avandra Imaging Emerges from Stealth to Solve a Last-Mile Problem in Medical Research appeared first on MedCity News.
pharmaphorum
OCTOBER 23, 2024
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by these manufacturers.
Speaker: Simran Kaur, Founder & CEO at Tattva Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Referral MD
OCTOBER 23, 2024
Prior authorization is a crucial healthcare topic related to the relationship between a patient, their healthcare provider, and the insurance company. This blog will outline everything you need to know about prior authorization , its definition, and its importance to healthcare. What is prior authorization? A patient’s physician or healthcare provider can decide what treatment the patient needs.
Fierce Pharma
OCTOBER 22, 2024
Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. The layoffs come three months after the company axed 150 positions in Sanford following a high-profile phase 3 trial failure for its Duchenne muscular dystrophy gene therapy candidate.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 22, 2024
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a statistically significant and clinically meaningful reduction in 24-hour urine protein-to-creatine ratio (uPCR) – a measure of how well the kidneys are working – after nine months of treatmen
Pharmaceutical Technology
OCTOBER 25, 2024
At the Outsourcing in Clinical Trials Conference, key opinion leaders shared predictions for workflow changes due to AI.
Fierce Pharma
OCTOBER 23, 2024
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines (PCV) from Pfizer and | The CDC's immunization committee voted to expand the recommendation for pneumococcal conjugate vaccines, including both Pfizer’s Prevnar 20 and Merck’s newer Capvaxive.
MedCity News
OCTOBER 20, 2024
Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. During the recent MedCity News INVEST Digital Health conference, a panel discussed these applications and more. The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
OCTOBER 25, 2024
Intellia reports a big reduction in hereditary angioedema attacks in patients treated with its one-shot CRISPR drug, but its share fall sharply
PharmaTech
OCTOBER 22, 2024
As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting the effectiveness of that therapy.
Fierce Pharma
OCTOBER 22, 2024
With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. | Following a string of high-profile deals, Samsung Biologics has locked down a $1.2 billion contract with an unnamed Asia-based pharmaceutical company that’s expected to run through December 2037. Samsung did not elaborate on the identity of its new partner or the types of drugs it will help produce under the accord.
MedCity News
OCTOBER 21, 2024
Recent failures in the retail health space beg the question: Is primary care only suited to remain within traditional players? Four healthcare executives shared their responses to this question during a panel at HLTH in Las Vegas. The post Can Primary Care Thrive Outside of Traditional Healthcare Players? appeared first on MedCity News.
pharmaphorum
OCTOBER 25, 2024
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.The programme represents the largest capital spend by the UK drugmaker on production capacity to date and will double the size and capacity of GSK's existing medicines and vaccines facility in Marietta, Pennsylvania, creating around 200 new jobs.
Spotio
OCTOBER 21, 2024
Designing sales territories has never been more important for door to door and field sales teams. Unfortunately, designing sales territories is a process that the majority of sales managers rush through. Aligning territory design with business priorities is crucial, as poor planning is a major issue impacting sales reps’ ability to meet quotas.
Fierce Pharma
OCTOBER 23, 2024
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and Wegovy, claiming the drugs are too complex to safely replicate.
MedCity News
OCTOBER 23, 2024
FarmboxRx CEO Ashley Tyrner explains why she never accepted outside capital after launching her company that serves nutritional needs of Medicaid and Medicare members. The post Video: Why This Startup CEO Never Accepted Outside Capital appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
OCTOBER 22, 2024
Sanofi is now in exclusive talks with private equity company Clayton Dubilier & Rice over the sale of a controlling stake in its consumer health business Opella, as the French government seeks guarantees it will keep production and jobs in France.
PharmaTech
OCTOBER 23, 2024
This article presents an overview of FDA’s recent update to the guidance document, Control of Nitrosamine Impurities in Human Drugs.
Fierce Pharma
OCTOBER 21, 2024
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. | As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.
MedCity News
OCTOBER 23, 2024
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation. The post Can Herbal Alternatives Ease the Economic Burden of Weight Loss Drugs? appeared first on MedCity News.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
OCTOBER 21, 2024
A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the data for the drug.Vabysmo (faricimab) has been approved by the FDA for treating DME since 2022, quickly becoming one of the Swiss pharma group's fastest-growing products with sales of $1.1 billion in the first half of the year.
Pharmaceutical Technology
OCTOBER 22, 2024
The European Union's CHMP has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua to treat ATTRv-PN.
Fierce Pharma
OCTOBER 22, 2024
With Johnson & Johnson sweetening the pot and mustering up the support of 83% of those who claim that the company’s talc products caused their cancer, it had
MedCity News
OCTOBER 24, 2024
This week at HLTH, FDA Commissioner Robert Califf discussed the current state of healthcare AI. He talked about some of the qualms he has, such as his worry that AI is worsening health inequities and his concern that providers aren’t capable of validating AI tools’ effectiveness. The post 4 Things That Worry FDA Commissioner Robert Califf appeared first on MedCity News.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
pharmaphorum
OCTOBER 21, 2024
Two digital therapeutics for addiction are available again through PursueCare, which acquired them from now-defunct Pear Tx last year
Pharmaceutical Technology
OCTOBER 23, 2024
A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.
Fierce Pharma
OCTOBER 25, 2024
Despite Merck & Co. | Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus antibody clesrovimab, Sanofi thinks Beyfortus can hold its own. On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more competition in the space is a net positive.
MedCity News
OCTOBER 21, 2024
The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2. It’s the first FDA-approved therapy for this target. The post Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer appeared first on MedCity News.
Expert insights. Personalized for you.
98 
Let's personalize your content